By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Illumina has once again rejected Roche's offer to acquire the firm and is urging its shareholders to also reject Roche's slate of nominees for Illumina's board of directors.

Last week, Roche upped its hostile takeover bid from $44.50 to $51 per share — an increase of 15 percent — now valuing the proposed deal at nearly $6.6 billion.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Guardian discusses whether big science projects are worth the loss of resources available for other scientific pursuits.

An NEJM update from the ClinVar team highlights the difficulties of interpreting genetic variants.

In Nature this week: genomic analysis of high-grade serous ovarian cancer, and more.

The new Riken president outlines some of his plans for the institute.